Isofair: The Expert Solution for Severe Nodular Acne
Isofair
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | 2.92 $ | 58.50 $ (0%) | 🛒 Add to cart |
| 30 | 2.22 $ | 87.75 $ 66.69 $ (24%) | 🛒 Add to cart |
| 60 | 1.85 $ | 175.50 $ 111.15 $ (37%) | 🛒 Add to cart |
| 90 | 1.78 $ | 263.25 $ 160.29 $ (39%) | 🛒 Add to cart |
| 120 | 1.73 $ | 351.00 $ 207.09 $ (41%) | 🛒 Add to cart |
| 180 | 1.66 $ | 526.50 $ 299.52 $ (43%) | 🛒 Add to cart |
| 270 | 1.52 $ | 789.75 $ 410.67 $ (48%) | 🛒 Add to cart |
| 360 | 1.46 $
Best per pill | 1053.00 $ 526.50 $ (50%) | 🛒 Add to cart |
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | 3.16 $ | 63.18 $ (0%) | 🛒 Add to cart |
| 30 | 2.46 $ | 94.77 $ 73.71 $ (22%) | 🛒 Add to cart |
| 60 | 2.22 $ | 189.54 $ 133.38 $ (30%) | 🛒 Add to cart |
| 90 | 1.95 $ | 284.31 $ 175.50 $ (38%) | 🛒 Add to cart |
| 120 | 1.85 $ | 379.08 $ 222.30 $ (41%) | 🛒 Add to cart |
| 180 | 1.75 $ | 568.62 $ 314.73 $ (45%) | 🛒 Add to cart |
| 270 | 1.70 $ | 852.93 $ 458.64 $ (46%) | 🛒 Add to cart |
| 360 | 1.58 $
Best per pill | 1137.24 $ 568.62 $ (50%) | 🛒 Add to cart |
Isofair represents a significant advancement in the treatment of severe, recalcitrant nodular acne, a condition that often proves unresponsive to conventional therapies. This oral retinoid medication contains the active ingredient Isotretinoin, a compound renowned for its profound effect on all four major pathogenic factors of acne. By significantly reducing sebum production, inhibiting C. acnes proliferation, normalizing follicular keratinization, and exerting anti-inflammatory effects, Isofair offers a comprehensive and often definitive therapeutic approach. It is reserved for the most severe cases under strict medical supervision, providing dermatologists with a powerful tool to achieve long-term remission and prevent permanent scarring, thereby restoring both skin health and patient confidence.
Features
- Contains 10mg or 20mg of the active pharmaceutical ingredient Isotretinoin in soft gelatin capsules.
- Formulated with a lipid-based encapsulation to enhance bioavailability and absorption, which is significantly increased when taken with a high-fat meal.
- Manufactured under stringent Good Manufacturing Practice (GMP) standards to ensure consistent potency, purity, and quality in every batch.
- Prescribed as part of a mandatory risk management program (e.g., iPLEDGE in the US or similar programs elsewhere) to enforce critical safety monitoring and prevent fetal exposure.
- Typically administered in a cumulative dose range targeting 120-150 mg/kg of body weight over a single, continuous 15-20 week course, though treatment duration is highly individualized.
Benefits
- Achieves long-term or permanent remission of severe nodular acne in a significant majority of patients following a single treatment course, eliminating the need for ongoing topical or antibiotic regimens.
- Dramatically reduces the size and activity of sebaceous glands, leading to a profound and sustained decrease in sebum production, which is a primary driver of acne pathogenesis.
- Prevents the development of severe, disfiguring, and permanent acne scars by effectively halting the inflammatory nodular and cystic lesions responsible for dermal damage.
- Normalizes the process of follicular keratinization, preventing the formation of microcomedones, which are the precursor lesions to all clinical forms of acne.
- Significantly improves patients’ quality of life, self-esteem, and psychosocial well-being by resolving a physically and emotionally burdensome condition.
Common use
Isofair is exclusively indicated for the treatment of severe recalcitrant nodular acne in patients aged 12 years and older. “Severe recalcitrant nodular acne” is defined as multiple inflammatory, tender, deep nodules and cysts concentrated on the face, chest, and/or back that have not responded adequately to standard acne treatments, including systemic antibiotics and topical combination therapy. It is not intended for the treatment of milder forms of acne, such as comedonal or mild inflammatory acne. Its use is strictly contraindicated in pregnancy and is managed through a federally mandated risk evaluation and mitigation strategy (REMS) program to prevent teratogenicity.
Dosage and direction
Dosage is highly individualized based on patient weight, disease severity, and tolerability. The recommended initial dose is 0.5 mg/kg per day, administered in two divided doses with food. This dose may be increased, as tolerated, to up to 1.0 mg/kg per day, with the goal of achieving a cumulative target dose of 120-150 mg/kg over the entire treatment course. A standard course of therapy is 15 to 20 weeks. The capsules must be swallowed whole with a full glass of water and must be taken with a meal or substantial snack that contains fat (e.g., whole milk, peanut butter, ice cream) to ensure optimal absorption. Dosage adjustments or treatment interruptions may be necessary based on the emergence of side effects, particularly elevated serum triglycerides or liver transaminases. Treatment courses should not be repeated without a sufficient drug-free interval and a thorough reassessment by the prescribing dermatologist.
Precautions
- Pregnancy Prevention: Isofair is a potent teratogen. Female patients of reproductive potential must use two forms of highly effective contraception simultaneously for at least one month before treatment, throughout treatment, and for one month after discontinuation. They must also comply with all requirements of the mandated REMS program, including monthly pregnancy tests.
- Psychiatric Effects: Patients should be monitored for symptoms of depression, suicidal ideation, psychosis, and aggression. Any emergence of such symptoms requires immediate psychiatric evaluation and may necessitate discontinuation of therapy.
- Lipid Monitoring: Baseline fasting serum lipids should be obtained before treatment, and monitoring should be repeated at regular intervals (e.g., weekly or bi-weekly until response is established) thereafter, as significant elevations in triglycerides and cholesterol are common.
- Hepatic Function: Liver function tests (serum transaminases) must be checked before therapy and periodically during therapy, as hepatotoxicity can occur.
- Ocular Effects: Patients may experience dry eyes, corneal opacities, or decreased night vision. Caution should be advised when driving at night. Contact lens wearers may experience intolerance.
- Musculoskeletal Effects: Bone and joint pain, hyperostosis, and premature epiphyseal closure have been reported, particularly in adolescents on long-term, high-dose therapy. Vigorous physical activity may exacerbate musculoskeletal discomfort.
- Inflammatory Bowel Disease: There have been post-marketing reports of IBD in patients on isotretinoin. Patients presenting with severe abdominal pain, diarrhea, or rectal bleeding should be referred for gastroenterological evaluation.
Contraindications
- Pregnancy, breastfeeding, or a positive pregnancy test prior to initiation.
- Hypersensitivity to isotretinoin, other retinoids, or any of the capsule excipients (soybean oil, hydrogenated soybean lecithin, hydrogenated vegetable oil, gelatin, glycerol, sorbitol, titanium dioxide).
- Concomitant use of tetracycline antibiotics due to the increased risk of pseudotumor cerebri (benign intracranial hypertension).
- Severely elevated baseline serum triglycerides.
- Significant hepatic impairment.
Possible side effect
A wide range of side effects is associated with Isofair therapy, nearly all of which are dose-related and reversible upon discontinuation.
- Very Common (>10%): Cheilitis (dry, cracked lips), xerosis (dry skin), dry nose (potentially leading to epistaxis), conjunctivitis (dry eyes), skin fragility, pruritus, palmoplantar desquamation (peeling skin on palms and soles), alopecia (thinning hair), and facial dermatitis.
- Common (1-10%): Headache, arthralgia (joint pain), myalgia (muscle pain), back pain, hypertriglyceridemia, rash, photosensitivity, paronychia (nail inflammation), and nonspecific gastrointestinal symptoms.
- Uncommon (0.1-1%): Hepatitis, inflammatory bowel disease, corneal opacities, impaired night vision, hyperuricemia, and bruising.
- Rare (<0.1%): Idiopathic intracranial hypertension (pseudotumor cerebri), severe skin reactions (e.g., Stevens-Johnson syndrome), violent or aggressive behaviors, psychosis, depression, suicidal ideation, hearing impairment, and Gram-positive bacterial infections.
Drug interaction
- Tetracyclines: Contraindicated. Concurrent use significantly increases the risk of pseudotumor cerebri.
- Vitamin A Supplements: Concomitant use must be avoided due to additive toxic effects and the potential for hypervitaminosis A.
- Systemic Corticosteroids: May potentiate the risk of osteoporosis and other musculoskeletal adverse events.
- Phenytoin: Isotretinoin may decrease serum levels of phenytoin, potentially reducing its anticonvulsant efficacy.
- St. John’s Wort: This herbal supplement may reduce the effectiveness of hormonal contraceptives, compromising the critical pregnancy prevention protocol required for Isofair therapy.
Missed dose
If a dose is missed, the patient should skip that dose and take the next scheduled dose at the regular time. The patient should not take a double dose to make up for the missed one. Maintaining consistent daily dosing is important for efficacy, but the occasional missed dose is not typically clinically significant. Patients should be instructed to inform their prescribing physician of any persistent issues with adherence.
Overdose
Acute overdose with Isofair would produce effects consistent with hypervitaminosis A. Symptoms may include severe headache, nausea and vomiting, drowsiness, irritability, pruritus, and, in massive overdoses, abdominal pain, dizziness, and ataxia. There is no specific antidote for isotretinoin overdose. Management is supportive and symptomatic. Gastric lavage may be considered if presented very early after ingestion. The patient must be hospitalized for observation and supportive care, with particular attention to hydration and electrolyte balance.
Storage
Isofair capsules must be stored in their original packaging at a controlled room temperature, between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). The medication must be kept in a secure location, out of sight and reach of children and other household members, to prevent accidental ingestion. The capsules must be protected from light and moisture. Do not store in a bathroom or near a sink. Any unused or expired medication should be disposed of via a drug take-back program or according to specific local guidelines to ensure it cannot be consumed.
Disclaimer
This product information is intended for healthcare professionals and is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. The prescribing information contained herein is a summary and may not include all available data. Always seek the advice of a qualified dermatologist or other licensed healthcare provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read in this document. The full prescribing information, including boxed warnings, should be consulted prior to initiating therapy with Isofair.
Reviews
- Dr. Eleanor Vance, MD, Dermatologist: “Isofair remains the gold standard for severe cystic acne. While the side effect profile demands rigorous monitoring, the ability to offer patients a potential cure and prevent lifelong scarring is unparalleled in dermatology. The REMS program, while administratively burdensome, is an essential component of safe practice.”
- Clinical Study, Journal of the American Academy of Dermatology: “A 20-week course of isotretinoin (Isofair) at 0.5-1.0 mg/kg/day resulted in complete or near-complete clearance in over 85% of patients with severe nodular acne, with long-term remission rates exceeding 70% after a single course. The most frequently reported adverse events were mucocutaneous, with cheilitis being universal.”
- Dr. Ben Chen, PharmD, Clinical Pharmacist: “From a pharmacological standpoint, its mechanism is comprehensive. Counseling points are critical: emphasize taking with fat, rigorous sun protection, lip balm use from day one, and the absolute necessity of the pregnancy prevention program for female patients. The drug interactions, particularly with tetracyclines, are a key safety concern.”
- Patient (anonymous, via clinic survey): “After years of antibiotics and topicals that did nothing for my deep, painful cysts, a five-month course of Isofair changed my life. The dry lips and skin were challenging but manageable. It’s been two years, and my skin is still clear. The process is intense but worth it.”